GRDN vs LFST
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GRDN presents a stark divergence between fundamental value and market price, with a Piotroski F-Score of 4/9 indicating only stable financial health. The stock is trading at a massive premium, with a current price of $37.93 compared to a Graham Number of $7.55 and an Intrinsic Value of $5.46. While growth metrics and analyst recommendations are strongly bullish, they are heavily offset by aggressive insider selling totaling over $419 million. The combination of extreme overvaluation and bearish insider sentiment outweighs the current growth trajectory.
LFST presents a stable but precarious financial profile with a Piotroski F-Score of 4/9 and no Altman Z-Score provided for bankruptcy risk assessment. While the company has successfully transitioned toward profitability with a promising forward P/E of 16.74, it trades at a massive premium compared to its Graham Number ($1.33) and Intrinsic Value ($0.14). Strong revenue growth of 17.4% is offset by razor-thin profit margins (0.68%) and aggressive insider selling totaling $32.51M. The stock is currently a speculative play on earnings expansion rather than a value-driven investment.
Compare Another Pair
Related Comparisons
GRDN vs LFST: Head-to-Head Comparison
This page compares Guardian Pharmacy Services, Inc. (GRDN) and LifeStance Health Group, Inc. (LFST) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.